Latest filing published 17 Jul 2023 for HERON THERAPEUTICS, INC. /DE/.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David Leslie Szekeres: trading record in brief
David Leslie Szekeres (chief executive) discloses dealings in Heron Therapeutics, Inc. /DE/ to SEC (Form 4). In total, 34 filings cover trades dated from 8 January 2021 to 13 July 2023.
Every open-market trade on record is a sale: 2 sales worth €70k. Besides market trades, the filings include 11 share grants and 18 option exercises.
On 17 July 2023 came the latest disclosure, a share grant for €2,348 in Heron Therapeutics, Inc. /DE/. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to David Leslie Szekeres
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,250 sharesCommon StockSEC:0001209191-23-042480:0
- 1,250 sharesCommon StockSEC:0001209191-23-024500:0
- 1,654 shares@ US$3.272549.7% of flowCommon StockSEC:0001209191-23-003564:0
- 1,250 sharesCommon StockSEC:0001209191-22-053836:0
- 1,505 shares@ US$3.84250.3% of flowCommon StockSEC:0001209191-22-042263:0
- 1,250 sharesCommon StockSEC:0001209191-22-024523:0
- 1,250 sharesCommon StockSEC:0001209191-22-003364:0
- 1,250 sharesCommon StockSEC:0001209191-21-060553:0
- 1,530 shares@ US$13.8975100.0% of flowCommon StockSEC:0001209191-21-046791:0
9 of 9 declarations
